Expertise in
18
conditions

Dr. Wells A. Messersmith

Oncology
Office
1665 Aurora Ct, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
18
conditions
Office
1665 Aurora Ct, 
Aurora, CO 

Overview

Wells Messersmith is an Oncologist practicing medicine in Aurora, Colorado.

Dr. Messersmith is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Hepato-Pancreato-Biliary Surgery, and Pancreatectomy.

He is actively involved in clinical research, co-authoring 177 peer reviewed articles and participating in 21 clinical trials. Dr. Messersmith is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CO

Hospital Affiliations

Uch-Memorial Health System
Uchealth Highlands Ranch Hospital
University Of Colorado Hospital Authority
Uchealth Broomfield Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
1665 Aurora Ct, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Enrollment Status: Recruiting
Publish Date: March 05, 2026
Intervention Type: Other
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: September 03, 2026
Intervention Type: Drug
Study Drugs: ALX148, Cetuximab, Pembrolizumab
Study Phase: Phase 2
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 21, 2026
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: FOLFIRINOX, Losartan, Nivolumab
Study Phase: Phase 2
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Phase: Phase 1
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Nab-paclitaxel, Gemcitabine
Study Phase: Phase 2
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2024
Intervention Type: Drug
Study Drugs: ETC-1922159, Pembrolizumab
Study Phase: Phase 1
Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors
Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Behavioral
Study Phase: Phase 3
A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
Enrollment Status: Suspended
Publish Date: September 22, 2023
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

177 Total Publications

Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases.
Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 01, 2026
Similar Doctors
Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Referral may be required

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (0.2 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rajeev Vibhakar is a Hematologist and an Oncologist practicing medicine in Aurora, Colorado. Dr. Vibhakar is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Gliomatosis Cerebri. Dr. Vibhakar is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.1 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Elias is an Oncologist practicing medicine in Aurora, Colorado. Dr. Elias is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Adult Soft Tissue Sarcoma, Liposarcoma, and Inflammatory Breast Cancer. Dr. Elias is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.1 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Lieu is an Oncologist practicing medicine in Aurora, Colorado. Dr. Lieu is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, Pancreatic Cancer, and Tissue Biopsy. Dr. Lieu is currently accepting new patients.

Frequently Asked Questions about Dr. Wells A. Messersmith

How do I make an appointment with Dr. Wells A. Messersmith?

You can book an appointment with Dr. Wells A. Messersmith by calling their office at 720-848-0300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Wells A. Messersmith a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Wells A. Messersmith is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Wells A. Messersmith specialize in?

While Dr. Wells A. Messersmith is a Oncology, they have specific expertise in Pancreatic Cancer, Colorectal Cancer, and Pancreatic Ductal Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Wells A. Messersmith participate in research or clinical trials?

Yes. Dr. Wells A. Messersmith has published 177 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Wells A. Messersmith's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Wells A. Messersmith accept my insurance?

Dr. Wells A. Messersmith accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 720-848-0300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Messersmith's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile